Effective particle-mediated vaccination against mouse melanoma by coadministration of plasmid DNA encoding gp100 and granulocyte-macrophage colony-stimulating factor

Clinical Cancer Research

Volumn 7, Issue 4, 2001, Pages 952-961

  Rakhmilevich, A L ^a   Imboden, M ^a   Hao, Z ^a   Macklin, M D ^a   Roberts, T ^a   Wright, K M ^a   Albertini, M R ^a   Yang, N S ^a   Sondel, P M ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DNA VACCINE; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 2; PLASMID DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; FEMALE; GENE TRANSFER; IMMUNOHISTOCHEMISTRY; MELANOMA; MOUSE; NONHUMAN; PLASMID; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINATION; VACCINE PRODUCTION;

ANIMALS; DISEASE MODELS, ANIMAL; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM PROTEINS; PLASMIDS; RECURRENCE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; VACCINATION;

EID: 0034910314     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions
2. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
3. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
4. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides
5. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen
6. Induction of a cytolytic T-cell response in mice with a recombinant adenovirus coding for tumor antigen P815A
7. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy
8. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
9. Virus treatment questioned after gene therapy death
10. Particle-mediated gene delivery system for cancer research
11. Gene gun and other non-viral approaches for cancer gene therapy
12. In vivo promoter activity and transgene expression in mammalian somatic tissues evaluated by using particle bombardment
13. In vivo cytokine gene transfer by gene gun reduces tumor growth in mice
14. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
15. Interleukin 2 gene transfer into tumor cells abrogates tumor-igenicity and induces protective immunity
16. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
17. Inhibition of tumor growth and enhancement of metastasis after transfection of the λ-interferon gene
18. An efficient Th2-type memory follows CD8 + lymphocyte-driven and eosinophil-mediated rejection of a spontaneous mouse mammary adenocarcinoma engineered to release IL-4
19. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
20. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma
21. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
22. Granulocyte-macrophage colony-stimulating factor (GM-CSF) secreted by cDNA-transfected tumor cells induces a more potent antitumor response than exogenous GM-CSF
23. Dual expression of human leukocyte antigen molecules and the B7-1 costimulatory molecule (CD80) on human melanoma cells after particle-mediated gene transfer
24. Particle-mediated gene transfer of granulocyte-macrophage colony-stimulating factor cDNA to tumor cells: Implications for a clinically relevant tumor vaccine
25. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
26. pMel17 is recognized by monoclonal antibodies NKI-beteb, HMB-45, and HMB-50 and by anti-melanoma CTL
27. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors
28. Interleukin 12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T cell-independent mechanism
29. Cloning, expression, and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100
30. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope
31. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
32. gp100/pmel 17 is a murine tumor rejection antigen: Induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand
33. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
34. Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity
35. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
36. Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization
37. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
38. Induction of antigen-specific tumor immunity by genetic and cellular vaccines against MAGE: Enhanced tumor protection by coexpression of granulocyte-macrophage colony-stimulating factor and B7-1
39. Immunotherapy of cancer with dendritic-cell-based vaccines
40. Immune selection after antigen-specific immunotherapy of melanoma
41. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination